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Abstract 
Purpose: To identify significant dysregulated miRNAs in postmenopausal osteoporosis in Chinese 
women and to test whether any of these miRNAs have diagnostic potential as circulatory biomarkers for 
postmenopausal osteoporosis.  
Methods: Thirty osteoporotic patients and 30 non-osteoporotic healthy individuals were recruited, and 
blood and bone tissue samples were collected from them. miRNA expression profiling and quantitative 
real-time polymerase chain reaction (qRT-PCR) were used to identify and substantiate dysregulated 
miRNAs in blood sera and bone tissue from osteoporotic patients. Receiver operating characteristic 
curve (ROC) analysis was carried out to assess the diagnostic potential of significantly dysregulated 
miRNAs.  
Results: Based on profiling and qRT-PCR, miR-125b, miR-30 and miR-5914 were significantly 
upregulated in the blood sera and bone tissues of patients with postmenopausal osteoporosis. In all the 
experiments carried out, miR-125b showed the highest levels of upregulation both in the blood sera and 
bone tissue compared to other upregulated miRNAs in osteoporotic patients. ROC analysis indicate that 
the AUC of miR-125b was the highest amongst the upregulated miRNAs.  
Conclusion: miR-125b is the highest significantly upregulated miRNA in postmenopausal osteoporosis. 
Furthermore, circulating miR-125b has the potential of a non-invasive biomarker for postmenopausal 
osteoporosis.  
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Osteoporosis is a disease wherein the bones 
become porous and the bone mineral density 
decreases thereby increasing the chances of 
broken bones. Numerous studies have shown 
that fragility of the bones is due to imbalances 
between bone resorption, responsible by 
osteoclasts and bone deposition, responsible by 
osteoblasts [1,2]. Statistical studies have shown 
that osteoporosis is more prevalent in women 
than in men with about 8% men and 38% women 
being affected in the developed world [3]. Post-
menopausal women constitute a high-risk group 
because of a direct correlation between 
dwindling estrogen levels and development of 
osteoporosis, ultimately resulting in the bones to 
become brittle and break [4]. 
  
MicroRNAs are small non-coding RNAs of 22-25 
nucleotides that have been shown to play 
indispensable regulatory roles in gene 
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expression in plant and animal kingdoms [5]. 
Since miRNAs are centerpieces of gene 
regulatory networks, varying expression levels of 
such regulatory miRNAs have been often 
associated with various types of cancers, 
cardiovascular diseases, neurodevelopmental 
diseases, autoimmune diseases and skeletal 
muscle diseases [6]. Accumulating evidence in 
the past few years have suggested that miRNAs 
play important regulatory roles in bone 
metabolism. Sugatani and Hruska have shown 
that miR-223 is expressed in mouse osteoclasts 
and plays a pivotal role in osteoclast 
differentiation [7]. Li et al have identified a 
previously unknown miRNA, miR-2861, that 
represses histone deacetylase 5 (HDAC5) 
expression thereby promoting osteoblast 
differentiation [8]. Further, they showed that miR-
2861 contributes to osteoporosis through its 
effect on osteoblasts. More recently, Xiao et al 
demonstrated the role of microRNA, miR-129-5p 
in osteoblast differentiation and bone 
homeostasis [9].  
 
Accumulating evidence in the last decade has 
suggested the diagnostic and prognostic 
potential of miRNAs in a variety of diseases, 
notably various types of cancer [10]. A most 
recent study identified a range of dysregulated 
miRNAs in osteoporosis related pathways and 
suggests miR-194-5p as a viable biomarker for 
postmenopausal osteoporosis [11]. Similarly, 
miR133a and miR422a have been identified as 
potential biomarkers for postmenopausal 
osteoporosis [12,13]. The present study aims to 
expand the repertoire of dysregulated miRNAs in 
postmenopausal osteoporosis and identify other 





Patient samples and characteristics 
 
The institutional review board and the ethical 
committee of Puai Hospital of Wuhan, China 
reviewed and approved the study (approval no. 
YX3254576) and written consent was obtained 
from every participant involved in this study. All 
procedures performed in this study involving 
human participants were in accordance with the 
ethical standards of the institutional and/or 
national research committee and with the 1964 
Helsinki declaration and its later amendments or 
comparable ethical standards [21].  
 
Thirty postmenopausal Chinese women with 
osteoporosis constituted the osteoporotic or the 
patient group. All the patients were past 
menopause in the age group of 59 – 80 years. 
The recruited patients carried hip fractures (in 
femoral neck, trochanter, and intertrochanteric 
regions) that required surgical intervention. This 
study did not recruit any patients having other 
medical issues such as malignancy or cancers, 
inflammation, diabetes, cardiovascular and 
metabolic disorders. Blood and bone tissue were 
collected from this postmenopausal osteoporotic 
patient pool and carefully harvested and stored 
for further analysis. The patient characteristics 
are summarized in Table 1. 
 
Isolation of RNA from serum and bone 
 
Five milliliters of blood was obtained from each 
patient and the blood was allowed to clot. 
Following clotting, the samples were centrifuged 
at 1500 g and the supernatant containing serum 
was isolated and stored. MiRNAs from the blood 
sera samples were isolated using Qiagen 
miRNeasy Serum/Plasma Kit (Qiagen, Hilden, 
Germany) according to the protocol provided in 
the handbook with minor modifications. The final 
RNA mixture was eluted in 20 μL of Rnase free 
water and stored at – 80 °C. miRNA from bone 
tissue was extracted using miRCURRY RNA 
Isolation Kit – Tissue (Exiqon Life Sciences, 
Copenhagen, Denmark) according to the 
instructions provided in the manual. The final 
RNA mixture was eluted in 20 μL of Rnase free 
water and stored at – 80 °C. 
 
 




Osteoporotic patients Non-osteoporotic patients 
(N = 30) N = 30 
Sex 30 females, 0 males 30 females, 0 males 
Age range (years) 59-80 62-75 
Height range (cm) 155-178 153-181 
Weight (kg) 62-96 58-103 
Body mass index, + SD 23.8 ± 5.7 25.2 ± 3.8 
Bone density (mg/dl), + SD 83.6 ± 19.9 197 ± 35.6 
Other medical condition None None 
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Quantitative real time polymerase chain 
reaction  
 
The dysregulated miRNAs were further validated 
by qRT-PCR and the RNA eluates were reverse 
transcribed to cDNA using TaqMan MicroRNA 
Reverse Transcription Kit (ThermoScientific, 
Waltham, USA) according to the instructions 
provided in the manual. Briefly, 10 ng of total 
RNA in reaction volume of 15 μL of reverse 
transcription reactions were prepared in 1.5 μL of 
10X RT buffer, 0.15 μL of 100 mM dNTPs, 0.2 μL 
of 20 units/μL RNase-inhibitor, 1 μL of each of 
microRNA primers (100 mM), 1 μL of MultiScribe 
Reverse Transcriptase (50 units/μL), and 10.15 
μL of DEPC treated water. The RT protocol was 
as follows: 18 °C for 30 min, 42 °C for 30 min 
and 90 °C for 5 min. Quantitative real-time PCR 
was performed on a 7900HT Fast Real-Time 
system (Applied Biosystems, California, USA). 
The reaction conditions were: 95 °C for 10 min 
and 35 cycles of 95 °C for 20 s and 58 °C for 1 
min. U6 RNA was used as endogenous control 
for all the reactions. The relative quantity of each 
miRNA was determined by 2-ΔΔCT method, where 
CT indicates cycle threshold, ΔCT = (CT target 
miRNA – CT endogenous control U6 RNA) and ΔΔCT= 
(ΔCT– average ΔCT of all the samples). 




The data analyzed are expressed as the mean ± 
standard deviation (SD). For analysis and 
determination of significance, two-tailed Mann-
Whitney U test or Student’s t-test was used. 
GraphPad Prism software (Version 6) was used 
to conduct statistical analysis. ROC curve 
analysis was used to determine the diagnostic 
potential of specific upregulated miRNAs. In all 
cases when interpreting the data, a value of p < 




Dysregulated miRNAs in the sera of 
postmenopausal osteoporosis patients 
 
A comprehensive miRNA expression profiling 
was carried out from a pool of 30 RNA samples 
isolated from patients with postmenopausal 
osteoporosis and from 30 healthy non-
osteoporotic Chinese women of the same age 
group, which served as control (Table 1). A total 
of 95 miRNAs could be detected in the array, and 
of those 95 detected miRNAs, 5 miRNAs (miR-
125b, miR-30, miR-4665-3p, miR-5914 and miR-
96) showed significant upregulation in the sera of 
postmenopausal osteoporotic patients compared 
to the healthy non-osteoporotic controls (Figure 
1). Amongst the five significantly upregulated 
miRNAs in postmenopausal osteoporotic 
patients, miR-125b was the most upregulated 
with a 12.67-fold change, followed by miR-4665-
3p with a 7.34-fold change, miR-96 with a 3.17-
fold change, miR-30 and miR-5914 both with a 
1.5-fold change compared to the samples from 
non-osteoporotic healthy individuals. 
 
miR-125b is significantly upregulated in 
serum of postmenopausal osteoporotic 
patients 
 
Using q-RTPCR, we validated whether any of the 
“best” dysregulated miRNAs, obtained by 
profiling, can be used as cues to distinguish 
serum samples of postmenopausal osteoporotic 
patients from that of non-osteoporotic healthy 
individuals. Since the data from qRT-PCR is 
more robust due to its much lower false positive 
rate than compared with profiling experiments, 
we resorted to the same to conclusively establish 
the plausibility of any such miRNA acting as a 
biomarker for postmenopausal osteoporosis. The 
qRT-PCR validation set consisted of serum 
samples from 30 postmenopausal osteoporotic 
patients and 30 non-osteoporotic healthy 
individuals. The expression levels of miR-4665-
3p and miR-96 were similar between the 
osteoporotic and non-osteoporotic sample group 
(Figure 2).  However, the levels of miR-125b, 
miR-30 and miR-5914 were higher in 
osteoporotic serum samples than the healthy 
ones (Figure 2). Between the above stated three-
upregulated miRNAs, miR-125b was the most 
significant suggesting that miR-125b has the 
potential as a biomarker for postmenopausal 
osteoporosis. 
 
Table 2:  Primer sequences used in the study 
 
Gene Forward primer (5'-3') Reverse primer (5'-3') 
U6 GCTTCGGCACATATACTAAAATA CGCTTCACGAATTTGCGTGT 
miR-30 GTGCCCAGATCAAGGTCGC CGACTGCGTGTCGACCAGC 
miR-96 GCTATGACGGAATCGCCAG CATGGTGCTTGTTGCGAGAT 
miR-125b GCCGACATGCTAGAAACGCCTC CCTAGCTGAGGTACACCCAGG 
miR-5914 GCGGGCGGATCGAATGATCGCG GCTAGGATGTCCGGATGGAGG 
miR-4665-3p GCGCGCGATCACGGCGTTACTAT CTACTGGACGGTAAAGCCGG 
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Figure 1: Expression profiling of miRNAs in the sera of postmenopausal osteoporotic patients with respect to 
healthy non-osteoporotic samples or control samples. It can be seen that all 5 miRNAs are significantly 
dysregulated, and of them, miR-125b shows maximum upregulation (p = 0.009) in the osteoporotic samples 




Figure 2: Substantiation of dysregulated miRNAs from profiling experiments by quantitative real time PCR. The 
miRNA expression levels were calculated by 2-ΔΔCT method. The expression levels of miR-96 and miR-4665-3p 
were similar between the osteoporotic group (OP) and the non-osteoporotic group (NOP). The expression levels 
of miR-30, miR-125b and miR5914 were higher in OP group than in NOP group. Amongst the three-upregulated 
miRNAs, miR-125b showed the highest levels of upregulation followed by miR-5914 and mi-30; * indicates p < 
0.05, ** indicates p < 0.03 and *** indicates p < 0.01) 
 
miR-125b is significantly upregulated in the 
bone tissues of postmenopausal 
osteoporotic patients 
 
We proceeded to investigate whether any of the 
dysregulated miR125b, miR30 and miR-5914 
could be detected in the bone tissues of 
postmenopausal osteoporotic patients. 
Consistent with the qRT-PCR results, the levels 
of all the three miRNAs were high compared with 
the healthy non-osteoporotic bone tissue, 
signifying upregulation of all three miRNAs 
(Figure 3). Between the three-upregulated 
miRNAs, the levels of miR-125b were 
significantly higher in the bone tissue of 
postmenopausal osteoporotic patients (Figure 3). 
These results are similar to the serum analysis 
further strengthening the potential of miR-125b 
as a biomarker for postmenopausal osteopo-
rosis. 
 
Diagnostic potential of miR-125b in 
postmenopausal osteoporosis 
 
To assess the diagnostic potential of miR-125b in 
postmenopausal osteoporosis, a routinely used 
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statistical method, receiver operating 
characteristic (ROC) curve analysis was 
performed. The ROC analysis was extended to 
miR-30 and miR-5914 to assess the diagnostic 
value of all these miRNAs. For each miRNA, the 
area under the curve (AUC), standard error and 
confidence interval was calculated (Figure 4). 
The AUC of miR-125b was calculated to be 
0.8944 (95 % confidence interval [CI] 0.9867-
0.9934, Standard error 0.00795), that of miR-30 
was calculated to be 0.7574 (95 % confidence 
interval [CI] 0.9153-0.9866, Standard error 
0.0312), and that of miR-5914 was calculated to 
be 0.6988 (95 % confidence interval [CI] 0.9517-
0.9864, Standard error 0.028). The AUC of miR-
125b was found to be the highest amongst the 
miRNAs and clearly suggest that miR-125b has a 
strong potential diagnostic value for 




Osteoporosis has been a growing heath concern 
in aging women in the developing world, 
especially in China [14]. Women that past are 
menopause, in particular, have been susceptible 
to osteoporosis eventually resulting in fragility 





Figure 3: miR-30, miR-125b and miR-5914 were significantly upregulated in the bone tissues of osteoporotic 
group (OP) compared to non-osteoporotic group (NOP). miR-125b showed highest levels of upregulation (p = 
0.0013) followed by miR-5914 (p = 0.0022) and miR-30 (p = 0.033). The miRNA expression levels in the bone 




Figure 4: Diagnostic potential of miR-5914, miR-30 and miR-125b for postmenopausal osteoporosis. ROC 
curves were plotted with sensitivity on the y-axis indicating a true positive rate and 1-specificity on the x-axis 
indicating false positive rate. The area under the curve (AUC) for each miRNA was estimated from the ROC 
curves. The AUC was found to be the best for miR-125b (0.8984) indicating a very good diagnostic potential, 
followed by miR-30 (0.7574) and miR-5914 (0.6988) 
 
This study has been designed and conducted to 
identify any potential miRNA that could serve as 
a biomarker for postmenopausal osteoporosis. 
By adopting a top-down approach, and using a 
combination of miRNA profiling followed by 
robust validation using quantitative real time 
PCR, this study revealed that miR-125b is 
significantly upregulated in the blood and bone 
tissue of postmenopausal osteoporotic patients, 
having promising diagnostic potential.   
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The identification of miRNAs as biomarkers for 
various disease conditions has been well 
established. Cumulating literary evidence in the 
past decade has suggested that miRNAs not 
only carry a wealth of information for the 
prognosis and diagnosis of a wide range of 
diseases but also are also useful in monitoring 
treatment response [10]. Till date, to the best of 
our knowledge, there have been only a handful 
of studies demonstrating the predictive value of 
specific miRNAs as biomarkers for osteoporosis. 
In one of such studies, 9 miRNAs were 
upregulated in the serum, 6 miRNAs in the bone 
tissue, and 5 miRNAs in both the serum and the 
bone tissue of osteoporotic patients, suggesting 
they may be used as biomarkers for diagnostic 
purposes [15]. Recently, miRNA expression 
analysis of circulating monocytes has been 
carried out in vivo and the study suggested miR-
133a as a potential biomarker for 
postmenopausal osteoporosis [12]. The afore-
stated study was one of its first kinds in 
identifying miR-133a as a biomarker in circulating 
monocytes. The same group identified another 
miRNA in circulating monocytes, miR-422a, as a 
potential biomarker for postmenopausal 
osteoporosis [13].  More recently, 5 dysregulated 
miRNAs in osteosarcoma were identified in 
microarray analysis and upon further subjection 
to pathway analysis only miR-194-5p was 
enriched in osteoporosis related pathways 
suggesting miR-194-5p as a potential biomarker 
for postmenopausal osteoporosis [11].  
 
In a quest to identify other potential miRNA 
biomarkers for postmenopausal osteoporosis, in 
the current study, serum and bone tissue from 30 
postmenopausal osteoporotic Chinese women 
were investigated for miRNA dysregulation. 
MiRNA profiling in the serum revealed 5 
miRNAs, namely miR-125b, miR-30, miR-4665-
3p, miR-5914 and miR-96 to be upregulated 
compared to healthy controls. Interestingly, miR-
125b showed maximum fold change when 
compared to other upregulated miRNAs. The 
major disadvantage of such profiling, owing to 
inherent technical limitations, is the high false 
positive rate resulting in erroneous results and 
interpretation. 
 
To perform a more stringent and robust analysis, 
qRT-PCR was used to substantiate the 
upregulated miRNAs. The analysis clearly 
indicated that the expression levels of miR-125b, 
miR-30 and miR-5914 were elevated in the 
serum of osteoporotic patients, with miR-125b 
showing the highest levels amongst all. This 
finding gave us initial clues that miR-125b could 
be a potential biomarker for postmenopausal 
osteoporosis. Previously, circulating miR-125b 
has been shown as a potential biomarker for 
Alzheimer’s disease [16], rectal adenocarcinoma 
[17], Ewing’s sarcoma [18], breast [19] and non-
small cell lung cancer [20].  To the best of our 
knowledge, there has not been any detailed and 
conclusive study suggesting the diagnostic 
potential of miR-125b in postmenopausal 
osteoporosis.  
 
The next step was to investigate whether any of 
these upregulated miRNAs were found at 
elevated levels in the bone tissue. Consistent 
with the qRT-PCR validation results, all the three 
miRNAs, miR-125b, miR-30 and miR-5914, were 
upregulated in the bone tissue of osteoporotic 
patients with miR-125b showing highest levels of 
expression. Taken together, this analysis 
indicates that miR-125b is significantly 
upregulated, in both sera and bone in 
postmenopausal osteoporotic patients. 
Additionally, the diagnostic potential of the 
upregulated miRNA pool was probed by ROC 
curve analysis that revealed miR-125b as the 





Altogether, the findings of the present study 
clearly demonstrate that miR-125b is significantly 
upregulated in postmenopausal osteoporosis and 
has the potential to serve as suitable and low-
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